Medical experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to improve global diagnosis and care [1], [2].
The change is intended to move the medical focus away from ovarian cysts alone and toward the broader hormonal and metabolic nature of the condition. By reframing the syndrome, health professionals aim to reduce the number of women who miss out on essential treatment due to a misleading name [3], [4].
Roughly 10% to 13% of women worldwide are affected by the condition [1]. Other reports estimate the prevalence as affecting one in eight women globally [4]. This hormonal syndrome carries lifelong consequences for millions of women [1], [4].
"Roughly 10% to 13% of women around the world are affected by a hormonal condition formerly known as PCOS. It's now called PMOS, or polyendocrine metabolic ovarian syndrome," Stephanie Sy said [1].
Experts announced the renaming on May 12, 2026 [2]. The previous terminology focused heavily on the presence of cysts, which did not always align with the systemic metabolic issues patients experienced. The new name specifically highlights the polyendocrine and metabolic aspects of the syndrome to provide a more accurate clinical picture [2], [5].
"It's a syndrome that affects one in eight women worldwide, with lifelong consequences, and yet the name was so misleading that many were missing out on diagnosis and treatment," a reporter for The Australian said [4].
USA Today staff said global experts renamed the condition to better reflect the hormonal, metabolic, and reproductive effects seen in women worldwide [2]. This shift in terminology is expected to guide physicians toward a more comprehensive approach to patient health—integrating metabolic screening with reproductive care [2], [6].
“The name was so misleading that many were missing out on diagnosis and treatment.”
The transition from PCOS to PMOS represents a shift in medical understanding from a localized organ issue to a systemic endocrine disorder. By removing the primary emphasis on 'cysts,' the medical community acknowledges that the syndrome's metabolic and hormonal drivers are more critical for diagnosis than the physical appearance of the ovaries. This change is likely to lead to earlier interventions for insulin resistance and other metabolic markers, potentially reducing long-term complications for millions of women.
